The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

Trial ID: NCT04979611

Interventional - Phase 1 - Unknown status

The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4 positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the patient diagnosed with endogenous hyperinsulinemic hypoglycaemia. And the diagnostic value will be performed. A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Conditions

• Insulinoma

Interventions

• 68Ga-NOTA-exendin-4

Eligibility

Inclusion criteria

• - 1.age ≥6 years old 2.Patients with hypoglycaemia 3.Endogenous hyperinsulinemic hypoglycaemia 4.Enhanced CT or MRI within 1 month 5.Signed written consent

Exclusion criteria

• - 1. Breast feeding 2.Pregnancy or the wish to become pregnant within 6 months 3.Renal function: serum creatinine during 41-73umol/L 4.Any medical condition may significantly interfere with study compliance; 5.Known allergy

Sponsor

First Affiliated Hospital of Fujian Medical University

Last updated: 2025-05-26 · Source: Clinicaltrials.gov

Search more clinical trials on myTomorrows